TNGX Logo

Tango Therapeutics, Inc. (TNGX) 

NASDAQ
Market Cap
$421.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
252 of 774
Rank in Industry
147 of 433

Largest Insider Buys in Sector

TNGX Stock Price History Chart

TNGX Stock Performance

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with …

Insider Activity of Tango Therapeutics, Inc.

Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $59.02M worth of Tango Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.44M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.

The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.

List of Insider Buy and Sell Transactions, Tango Therapeutics, Inc.

2024-11-18Purchasedirector
10,000
0.0098%
$3.78$37,800-4.76%
2024-11-14Purchasedirector
10,000
0.0088%
$3.62$36,2000.00%
2024-11-07Sale10 percent owner
1.21M
1.1237%
$2.94$3.54M+27.03%
2024-11-06Sale10 percent owner
1.49M
1.3103%
$3.28$4.9M+9.88%
2024-11-06SaleSee remarks
3.08M
2.5882%
$3.14$9.67M+9.88%
2024-10-25SaleSee remarks.
633,000
0.6113%
$6.87$4.35M0.00%
2024-10-22SaleSee remarks
250,000
0.2383%
$6.78$1.7M0.00%
2024-10-21SaleSee remarks
625,000
0.5752%
$7.05$4.41M-46.15%
2024-09-13Sale10 percent owner
67,400
0.0631%
$10.53$709,756-34.52%
2024-09-05Sale10 percent owner
75,000
0.0693%
$11.56$867,135-40.84%
2024-08-30Sale10 percent owner
175,000
0.1601%
$11.60$2.03M-40.96%
2024-08-27Sale10 percent owner
25,000
0.0236%
$11.55$288,665-38.60%
2024-08-19Sale10 percent owner
150,000
0.1323%
$10.09$1.51M-33.05%
2024-08-16Sale10 percent owner
135,000
0.1454%
$9.79$1.32M+2.01%
2024-08-01Sale10 percent owner
40,000
0.0388%
$9.80$392,000-18.62%
2024-07-31Sale10 percent owner
100,000
0.0958%
$9.93$993,3800.00%
2024-07-30Sale10 percent owner
95,000
0.0898%
$9.80$931,1140.00%
2024-07-26Sale10 percent owner
50,000
0.0472%
$9.84$491,950-21.03%
2024-07-25Sale10 percent owner
100,599
0.0943%
$9.87$992,771-18.88%
2024-07-24Sale10 percent owner
200,000
0.1854%
$9.82$1.96M0.00%

Insider Historical Profitability

31.51%
Rothenberg Macedirector
31250
0.0291%
$3.9220
Boxer Capital, LLC
8198642
7.6325%
$3.9231
Davis Aaron I.director
7123642
6.6317%
$3.9230+36.98%
LEWIS JOSEPHdirector
7053642
6.5665%
$3.9230+39.17%
BCTG Holdings, LLC10 percent owner
4488450
4.1785%
$3.9211+7.42%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Trv Gp Iv Llc$152.46M17.9719.2M-0.84%-$1.29M73.88
Ecor1 Capital Llc$105.85M12.4813.33M0%+$00.74
Fidelity Investments$75.36M8.889.49M-3.02%-$2.35M0.01
Boxer Capital, LLC$65.1M7.678.2M0%+$01.33
Nextech Invest$43.94M5.185.53M0%+$07.16
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.